Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor-open, Placebo-controlled, Single- And Multiple-dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Cp-601,927 In Healthy Japanese Subjects

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor-open, Placebo-controlled, Single- And Multiple-dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Cp-601,927 In Healthy Japanese Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CP 601927 (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 27 Oct 2018 Planned End Date changed from 1 Oct 2011 to 29 Oct 2011.
  • 27 Oct 2018 Planned primary completion date changed from 1 Oct 2011 to 29 Oct 2011.
  • 27 Oct 2018 Planned initiation date changed from 1 Aug 2011 to 26 Aug 2011.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top